Advertisement Valeant Pharma acquires AB Sanitas - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Valeant Pharma acquires AB Sanitas

Valeant Pharmaceuticals, a developer, manufacturer and marketer of a range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics, has acquired AB Sanitas.

Previously, Valeant signed a deal to take over Lithuania-based specialty pharmaceuticals company AB Sanitas for around EUR314m.

Sanitas has a range of branded generics product portfolio consisting of 390 products in nine countries throughout Central and Eastern Europe, primarily Poland, Russia and Lithuania.

The company has in-house development capabilities in dermatology, ophthalmology and hospital injectables and also a pipeline of internally developed and acquired dossiers.